logo

Aldeyra Therapeutics, Inc. (ALDX)



Trade ALDX now with
  Date
  Headline
11/9/2017 7:36:10 AM Aldeyra Therapeutics Q3 Loss Per Share $0.32 Vs Loss $0.38 Last Year
10/24/2017 8:11:39 AM Aldeyra Therapeutics Presents Evidence For Aldehyde Sequestration As Potential Therapeutic Approach
10/5/2017 8:09:15 AM Aldeyra Presents Novel Data On The Efficacy Of ADX-102 In Model Of Succinic Semialdehyde Dehydrogenase Activity
9/19/2017 8:59:01 AM Aldeyra Therapeutics Prices Public Offering Of 3.45 Mln Common Shares At $7.25 Per Share
9/18/2017 4:03:56 PM Aldeyra Therapeutics Announces Proposed Public Offering Of Common Stock
9/12/2017 7:07:13 AM Aldeyra Therapeutics Says Positive Results From A Phase 2a Clinical Trial Of ADX-102 In Patients With Dry Eye Disease
8/8/2017 7:39:17 AM Aldeyra Therapeutics Q2 Net Loss Per Share $0.35 Vs Loss $0.41 Last Year
6/14/2017 6:51:45 AM Aldeyra Reports Results From Allergic Conjunctivitis Phase 2b Clinical Trial And Plans For Phase 3 Clinical Testing
6/14/2017 12:33:59 AM Keep An Eye On ALDX Today
5/15/2017 7:50:19 AM Aldeyra Therapeutics Q1 Net Loss $5.1 Mln Vs. Net Loss Of $5.0 Mln Prior Year
4/20/2017 8:07:09 AM Aldeyra Therapeutics Gets Orphan Drug Designation From The US FDA For ADX-102 In Sjögren-Larsson Syndrome